IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Artificial Intelligence in the Pharmaceutical Sector of India: Future Prospects and Challenges

Aprajita Kimta

Ph.D. Research Scholar, Department of Economics, Himachal Pradesh University, Shimla,

Dr Reena Dogra

Assistant Professor, Department of Economics, Himachal Pradesh University, Shimla,

Abstract

The pharmaceutical sector in India has emerged as a global leader, contributing significantly to the production of affordable generic drugs and vaccines. Despite its success, the industry faces challenges from early research and development stages to market deployment. This research paper explores the future prospects and challenges of integrating Artificial Intelligence (AI) into the Indian pharmaceutical sector. Methodologically, the research relies on secondary data from 2011 to 2019, collected from various published sources, primarily the Reserve Bank of India. The evaluation of performance was conducted using compound annual growth rate. AI has the potential to address longstanding issues, enhance operational efficiency, and reduce costs associated with drug discovery and development. Successful integration requires collaborative efforts from the public and private sectors, emphasizing resource allocation for education, infrastructure, regulatory reforms, and workforce development. The incorporation of AI presents a transformative opportunity for the Indian pharmaceutical sector, offering advancements in drug development, manufacturing, and quality control. Despite the promising prospects, the paper acknowledges challenges in implementing AI, including financial limitations, workforce competency, data security concerns, and regulatory complexities. The study emphasizes the need for strategic collaboration to ensure responsible and effective utilization of AI in the pharmaceutical industry.

Keywords: Artificial intelligence, Pharmaceutical Sector, Drug Development, Research and development, Manufacturing, and Quality control.

1. Introduction

The Indian pharmaceutical industry has emerged as a global leader, renowned for its production of affordable generic drugs and vaccines, underscoring its significance as a dynamic and influential sector on the international stage. Holding the third position in pharmaceutical production globally based on volume, India has carved a niche for itself in the manufacturing of generic pharmaceuticals and vaccines. The industry's vast landscape comprises

numerous pharmaceutical enterprises, collectively establishing the region as a substantial contributor to the global healthcare sector. Over time, the Indian pharmaceutical industry has witnessed remarkable expansion and transformation, mirroring advancements in research, development, and production capabilities. This evolution has positioned the sector as a key player in addressing global health concerns by supplying high-quality drugs to diverse nations. The industry's impact extends beyond geographical borders, exerting a significant influence on the global healthcare environment. However, like many countries the Indian pharmaceutical sector is characterised by challenges. These challenges include expensive and lengthy processes involved in developing new drugs. These expenditures begin with the scanning of millions of components during the initial phases of research and development (R&D) and conclude with high-cost clinical trials that often yield unpredictable outcomes. AI has the potential to be the solution to longstanding challenges in the industry, including issues related to time and the costs associated with drug development (Kalyane *et al.*, 2020). AI can enhance the effectiveness of drug development processes, fostering collaboration between major players in the pharmaceutical industry and companies specializing in AI-driven drug discovery (Mak and Pichika, 2019). Most pharmaceutical companies recognize the necessity of harnessing the potential of emerging technologies. Researchers believe that the next evolutionary phase in the development of the pharmaceutical industry could involve the integration of Big Data and AI algorithms (Bhattamisra *et al*., 2023). Through the processing and analysis of graphic data and text, AI has the capability for quicker and more precise analysis compared to humans or alternative technologies. AI has the potential to enhance operational efficiency and lower the costs associated with drug discovery and development within the pharmaceutical sector (Vyas, M. *et al*., 2018). Artificial intelligence (AI) involves replicating human intelligence in machines, allowing them to emulate human thinking and behaviours. These characteristics grant AI the capability to take actions aimed at achieving particular objectives effectively. AI constitutes the scientific domain encompassing machines capable of executing tasks such as logic, reasoning, planning, learning, and perception (Mak *et al*., 2022). AI represents a technology-centered system comprising a range of sophisticated tools and networks designed to replicate human intelligence, without posing a complete threat to entirely replace human physical presence (Yang and Siau, 2018). AI functions as a highly effective tool for tasks such as identifying the best solutions for problems, recognizing patterns, and categorizing data (Adir *et al*., 2019). AI holds the potential to address unresolved issues within the industry, particularly regarding time constraints and the expenses. In recent times, AI has extended its influence into pharmaceutical and healthcare domains, covering a wide range of functions such as drug discovery and design, enhancing product development, improving manufacturing processes, ensuring proper drug adherence and dosing, forecasting treatment outcomes, identifying candidates for clinical trials, managing rare diseases and personalized medicine, conducting medical imaging, detecting outbreaks of pandemic diseases, and so on (Kalyane *et al*., 2020). This study aims to explore the growing potential of AI and addressing challenges within the pharmaceutical industry, serving as its primary motivation.

2. Methodology and Technique of Analysis

The present study is primarily based on secondary data. Product data on export earnings for 2011 to 2019 is taken from Reserve Bank of India.

2.1 Estimation of Growth Rates

Compound Annual Growth Rate (CAGR) : Compound growth rates indexes are calculated by fitting an exponential function described as follows:

$$Y_t = \alpha\, \beta^t\, \varepsilon^{ut}$$

Where Y_t is export value of pharmaceutical products in India in time period t, α and β are unknown parameters, u is disturbance term, t is time period. The equation can be written in logarithmic form as follows:

$$\log Y_t = \log\alpha + t \log\beta + u_t$$

Ordinary least square method is applied to compute the values of unknown parameters log α and log β. Thereafter, compound annual growth rate will be enumerated by multiplying the residual, obtained by subtraction of unity from antilog of estimated regression coefficient logβ, with 100 (Madnani, 2003) as under:

$$\text{CAGR (Y)} = (\text{antilog}\ \beta_1 - 1)^* 100$$

3. Pharmaceutical Market in India

Before diving into the prospects of AI in the Indian pharmaceutical industry, it's essential to understand the current state of this sector. The pharmaceutical market in India is a dynamic and rapidly growing industry, positioned as a global pharmaceutical powerhouse. The industry is known for producing high-quality generic medicines at competitive prices, contributing significantly to global healthcare affordability. India ranks as the third-largest pharmaceutical industry worldwide by volume and the 14th largest concerning its value. The pharmaceutical sector contributes approximately 1.72 percent to the country's GDP. The pharmaceutical sector stands among the top ten appealing industries for foreign investment in India. India's pharmaceutical exports extend to over 200 countries globally, encompassing rigorously regulated markets such as the USA, China, Japan, and Germany. India is a major player in the worldwide pharmaceutical and vaccination markets. It is the world's biggest supplier of generic medications. Due to the excellent quality and affordability of its medicines, India is appropriately recognized as the "pharmacy of the world." (Pharmaceutical Annual report 2022-23).

Table 1. Exports of Pharmaceutical Products of India

Year	Export of Medicinal and pharmaceutical products (Rs in crores)
2011	476.62
2012	630.21
2013	784.88
2014	904.15
2015	943.5
2016	1105.34
2017	1125.5
2018	1114.1
2019	1339.41
CAGR	11.93357

(Source: Reserve Bank of India)

The analysis of historical data spanning from 2011 to 2019 pertaining to the export profits derived from medicinal and pharmaceutical items within the Indian pharmaceutical industry presents a persuasive account of sustained expansion and steadfastness. In the year 2011, the industry achieved export revenues amounting to 476.62 million units of currency. Subsequently, this number exhibited a notable rising trend in the following years. By the year 2019, the export profits had seen a significant jump, reaching a total of 1339.41 million units. This notable growth is observed when comparing the data to the previous eight-year period. Significant increases in profits were found over select time periods, namely between 2015 and 2016, as well as between 2018 and 2019, suggesting periods of rapid development and expansion within the business. The CAGR of pharma exports from 2011 to 2019 was 11.93357. The observed oscillations may be ascribed to many causes, including heightened worldwide demand, effective market penetration, and the possible launch of novel pharmaceutical goods. The persistent and upward trajectory indicates the pharmaceutical industry's strong and substantial impact on the Indian economy, demonstrating its ability to withstand challenges and compete effectively in the international arena. In light of the historical context, the incorporation of sophisticated technologies like as Artificial Intelligence (AI) and data analytics is seen as a crucial need for the industry. This integration has the potential to enhance efficiency, foster innovation, and increase export revenues in the coming years.

The promising trajectory of export earnings from medicinal and pharmaceutical products in the Indian pharmaceutical sector from 2011 to 2019 sets the stage for a future where the integration of advanced technologies like Artificial Intelligence (AI) and data analytics is poised to further amplify sector performance. As demonstrated by the historical data, the adoption of AI has the potential to revolutionize drug discovery processes, expediting timelines and enhancing efficiency in identifying novel drug candidates. Looking ahead, AI's ability to analyze vast datasets will likely contribute to even more precise and accelerated drug development, translating into increased export earnings. Predictive analytics, a cornerstone of data analytics, is expected to play a pivotal

role in optimizing clinical trial designs, predicting patient responses, and improving overall trial success rates. This not only ensures the sector's sustained growth but also positions it as a leader in adopting innovative approaches. Moreover, the ongoing integration of AI in supply chain management is anticipated to provide real-time insights, reducing operational inefficiencies and bolstering the integrity of pharmaceutical products, which will likely contribute significantly to future export earnings. The journey towards personalized medicine, facilitated by AI-driven technologies, is expected to gain momentum, catering to individualized patient needs and fostering global competitiveness. In essence, the convergence of historical export data with the potential future impact of AI and data analytics signifies a dynamic and progressive trajectory for the Indian pharmaceutical sector, pointing towards increased efficiency, innovation, and global prominence in the years to come.



(Source: Indian Economic survey 2022-23)

The above graph shows that Indian pharmaceutical sector is anticipated to achieve a market valuation of about US$ 65 billion by 2024 and potentially reach approximately US$ 130 billion by 2030. The remarkable and rapid compound annual growth rate projected for the years spanning from 2021 to 2030 indicates the extraordinary transformation that AI is poised to bring to the pharmaceutical and related industries in the near future. Utilizing computer software and AI-driven algorithms can aid pharmaceutical companies in cutting costs linked to clinical trials, lowering the likelihood of molecule failures, thereby saving crucial time. Furthermore, AI offers an enhanced platform for streamlined drug design and development, facilitating efficient drug design and accelerating progress within the pharmaceutical sector.

4. AI in the lifecycle of Pharmaceutical Product

AI plays a crucial role throughout the lifecycle of pharmaceutical products, from early research and development stages to market deployment.



Figure 1. The intervention of AI in the different divisions of the pharmaceutical sector

4.1 AI in Research and Development

The pharmaceutical research and development process is highly complex, demanding extensive knowledge and costly affair (Bhattamisra *et al*., 2023). Therefore, pharmaceutical scientists must embrace new technologies that offer quicker solutions compared to the traditional trial-and-error methods. Utilizing software-based technologies like AI can significantly aid in advancing research and development within the field. Several companies, including Novartis, Bioxel, and Qrativ, are actively engaging in AI-driven research and development initiatives globally. AI applications offer significant advantages by safeguarding and providing easily accessible stored knowledge. These systems ensure consistent formulation development, reducing both time and costs, thereby accelerating the entire process. Utilizing tools like AI is poised to enhance success rates in research and development within the field. (Mitchell, 2018).

4.2 AI in Drug Discovery

Advanced drug development is a major benefit of AI in the pharmaceutical business. Traditional drug development involves lengthy timescales, large costs, and significant failure rates (Yang *et al*., 2019). AI-driven algorithms may find tiny patterns and links in complicated biological data, helping researchers choose substances for testing. Virtual screening speeds up the discovery of potential medication candidates, helping pharmaceutical corporations manage resources. Machine learning algorithms can find intervention targets by analysing genetic data, pointing researchers to the most promising locations. AI systems analyse genetic, lifestyle, and treatment

data in personalised medicine, a new healthcare paradigm. This allows the creation of more effective and safer medicines that are personalised to each patient's genetics. AI in drug research raises ethical, data privacy, and regulatory issues (Luna *et al*., 2021).

In conclusion, AI in drug development will revolutionise the pharmaceutical business by lowering the time and resources needed to develop new medications. AI's capacity to analyse massive databases, find drug candidates, and personalise treatment methods might revolutionise pharmaceutical research and development resulting in more effective and customised therapies (Paul *et al*., 2021)

4.3 AI in Pharmaceutical Manufacturing

The integration of Artificial Intelligence (AI) into the industrial sector in India has significant potential for enhancing the performance and competitiveness of the industry. The integration of artificial intelligence (AI) technology with manufacturing processes, has the potential to bring about a significant transformation in conventional methods (Chaudhary *et al*., 2023). This integration is expected to enhance efficiency, accuracy, and innovation within the manufacturing sector. The use of AI-driven applications, such as predictive maintenance, has promise in reducing downtime and improving overall equipment effectiveness via the anticipation of equipment faults prior to their actual occurrence. The use of this proactive strategy not only serves to reduce interruptions in production, but also enhances the efficiency of resource allocation and decreases maintenance expenses (Manzano and Whitford, 2023). In addition, the use of artificial intelligence (AI) in conjunction with robotic automation and smart manufacturing systems allows for the efficient integration of data across the entire value chain. This integration enables timely decision-making and improves the flexibility of production processes. Machine learning algorithms provide the capability to analyse extensive datasets, leading to the optimisation of production schedules, inventory management, and quality control (Rathore *et al*., 2023). Consequently, these advancements contribute to the enhancement of overall operational efficiency. Furthermore, the use of artificial intelligence (AI) in the development of intelligent supply chains plays a crucial role in enabling businesses in India to adapt promptly to market needs, minimise risks, and attain enhanced sustainability. The integration of artificial intelligence (AI) and the Internet of Things (IoT) into the manufacturing facilitates the establishment of linked ecosystems, hence promoting improved communication and cooperation across different components of the production process (Arden *et al*., 2021). Despite the presence of skill gaps and the need for infrastructure development, it is evident that AI has a profound and transformative effect on the manufacturing industry in India. This impact not only leads to enhanced productivity but also positions the sector to flourish amidst the rapid evolution of technology and global competition (Sharma *et al*., 2023)

4.4 AI and Quality Control and Quality Assurance

The creation of a pharmaceutical formulation within the designated timeframe while guaranteeing quality is an intricate process that demands a carefully organized and scientific method. Machine learning techniques, such as neural networks and decision trees, have a significant impact on the identification of flaws and deviations via the analysis of historical data patterns (Zhao *et al*., 2006). This capability facilitates the early diagnosis and prevention

of quality concerns. Furthermore, the AI algorithms demonstrate proficiency in predictive modelling by using data from various phases of pharmaceutical production to optimise procedures, resulting in improved operational effectiveness and decreased manufacturing expenses (Kulkov, 2021). In contemporary times, computer vision systems are used in the field of pharmaceuticals to apply image recognition techniques for the purpose of visually examining pharmaceutical items in order to identify any faults. This serves the purpose of assuring strict adherence to quality standards and detecting errors that are frequently undetectable to human inspectors. The use of computer vision in real-time monitoring of industrial processes to detect abnormalities and deviations is a significant contribution (Paul *et al*., 2021). In aggregate, the integration of these artificial intelligence (AI) technologies serves to enhance the overall strength and effectiveness of the quality control and assurance system (Ranebennur *et al*., 2023).

4.5 AI in Pharmaceutical Product Management

AI technologies enable pharmaceutical companies to strategically position their products by analyzing market trends, competitor activities, and consumer preferences (Aggarwal *et al*., 2021). Predictive analytics powered by AI can enhance market forecasting, anticipating demand fluctuations and optimizing production accordingly, thereby mitigating potential economic risks (Toker *et al*., 2013). Furthermore, in the realm of product costing, AI facilitates a more precise estimation of expenses involved in drug development, manufacturing, and distribution. This can lead to more informed pricing strategies, ensuring competitiveness in the market while maintaining economic sustainability (Paul *et al*., 2021).

5. Challenges in the Implementation of AI

The pharmaceutical industry faces a range of significant hurdles such as financial limitations for investments, the requirement for a proficient workforce, apprehensions regarding data security and privacy, navigating a multifaceted regulatory environment, insufficient internet connectivity in numerous areas, and successful implementation of this change requires collaborative endeavours from both the public and commercial sectors, with a particular focus on allocating resources towards education, infrastructure, regulatory reforms, and workforce development (Selveraj *et al*., 2021, Tangi *et al*., 2023). Furthermore, ensuring the ethical use of AI in drug development remains a critical concern, necessitating the establishment of clear guidelines and ethical frameworks (Shaw *et al*., 2019). The pharmaceutical industry also grapples with the rapid pace of technological advancements and the need for continuous adaptation to stay competitive. The dynamic nature of scientific research and the evolving landscape of healthcare demand constant innovation. Successful navigation of these challenges requires collaborative efforts across industries, academia, and policymakers.

6. Conclusion

The incorporation of artificial intelligence in the pharmaceutical sector presents a transformative opportunity for India to bolster in pharmaceutical industry. The field of Artificial Intelligence (AI) will bring about significant

transformations throughout the whole life cycle of pharmaceutical goods, presenting remarkable progress in areas ranging from medication development to production and quality control. Machine learning algorithms and data analytics will significantly reduce the time and resources required for the identification of new drug candidates in the field of drug discovery. This will result in accelerated medication development and facilitated the implementation of personalised treatment approaches via precision medicine. The use of artificial intelligence (AI) in the pharmaceutical manufacturing sector, will result in improved operational effectiveness, precision, and advancement. AI applications, such as predictive maintenance, will be crucial in reducing periods of inactivity and optimising the allocation of resources. The integration of artificial intelligence with robotic automation and smart manufacturing systems allows for the seamless integration of data, which in turn enables prompt decision-making and enhances the flexibility of production processes. Moreover, the function of artificial intelligence in quality control and assurance is of utmost importance. AI utilises machine learning techniques to spot flaws at an early stage, employs computer vision to monitor processes in real-time. Notwithstanding the considerable advantages brought about by AI implementation, the pharmaceutical sector encounters many obstacles including limited financial resources, workforce competency, apprehensions about data security, and the intricate nature of regulatory frameworks. Ethical considerations and the dynamic nature of technological advancements further underscore the need for clear guidelines and ongoing innovation. The achievement of successful integration in the pharmaceutical sector requires joint endeavours, with a particular focus on allocating resources towards education, infrastructure, regulatory changes, and workforce development. This approach is crucial in order to ensure the responsible and effective utilisation of artificial intelligence (AI).

References

1. Zhao, C., Jain, A., Hailemariam, L., Suresh, P., Akkisetty, P., Joglekar, G., et al. (2006). Toward intelligent decision support for pharmaceutical product development. Journal of Pharmaceutical Innovation, 1, 23-35.
2. Yang, S. S., Lu, W. C., Gu, T. H., Yan, L. M., & Li, G. Z. (2009). QSPR Study of n-Octanol/Water Partition Coefficient of Some Aromatic Compounds Using Support Vector Regression. QSAR & Combinatorial Science, 28(2), 175-182.
3. Toker, D., Tozan, H., & Vayvai, O. (2013). A decision model for pharmaceutical marketing and a case study in Turkey. Economic Research-Ekonomska Istraživanja, 26(1), 101-114.
4. Mishra, V. (2018). Artificial intelligence: The beginning of a new era in pharmacy profession. Asian Journal of Pharmaceutics (AJP), 12(02).
5. Mitchell, J. B. (2018). Artificial intelligence in pharmaceutical research and development. Future Medicinal Chemistry, 10(13), 1529-1531.
6. Mak, K.-K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and future prospects. Drug Discovery Today, 24(3), 773-780.
7. Shaw, J., Rudzicz, F., Jamieson, T., & Goldfarb, A. (2019). Artificial intelligence and the implementation challenge. Journal of Medical Internet Research, 21(7), e13659.
8. Kalyane, D., Sanap, G., Paul, D., Shenoy, S., Anup, N., Polaka, S., & Tekade, R. K. (2020). Artificial intelligence in the pharmaceutical sector: Current scene and future prospect. In The Future of Pharmaceutical Product Development and Research (pp. 73-107). Academic Press.
9. Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., ... & Schroeder, A. (2020). Integrating artificial intelligence and nanotechnology for precision cancer medicine. Advanced Materials, 32(13), 1901989.
10. Colombo, S. (2020). Applications of artificial intelligence in drug delivery and pharmaceutical development. In Artificial Intelligence in Healthcare (pp. 85-116). Academic Press.

11. Kulkov, I. (2021). The role of artificial intelligence in business transformation: A case of pharmaceutical companies. Technology in Society, 66, 101629.
12. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. Drug Discovery Today, 26(1), 80.
13. Das, S., Dey, R., & Nayak, A. K. (2021). Artificial intelligence in pharmacy. Indian Journal of Pharmaceutical Education and Research, 55 (2), 304-318.
14. Jiménez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G. (2021). Artificial intelligence in drug discovery: Recent advances and future perspectives. Expert Opinion on Drug Discovery, 16(9), 949-959.
15. Agarwal, S., Gupta, R. K., & Kumar, S. (2021). Artificial Intelligence in the Pharmacy Profession. International Journal of Research in Pharmaceutical Sciences, 12, 2269-2279.
16. Selvaraj, C., Chandra, I., & Singh, S. K. (2021). Artificial intelligence and machine learning approaches for drug design: Challenges and opportunities for the pharmaceutical industries. Molecular Diversity, 1-21.
17. Arden, N. S., Fisher, A. C., Tyner, K., Lawrence, X. Y., Lee, S. L., & Kopcha, M. (2021). Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. International Journal of Pharmaceutics, 602, 120554.
18. Khan, S. R., et al. (2021). Integration of AI and traditional medicine in drug discovery. Drug Discovery Today, 26(4), 982-992.
19. Mak, K.-K., Balijepalli, M. K., & Pichika, M. R. (2022). Success stories of AI in drug discovery-where do things stand? Expert Opinion on Drug Discovery, 17(1), 79-92.
20. . Chaudhary, S., Muthudoss, P., Madheswaran, T., Paudel, A., & Gaikwad, V. (2023). Artificial intelligence (AI) in drug product designing, development, and manufacturing. In A Handbook of Artificial Intelligence in Drug Delivery (pp. 395-442). Academic Press.
21. Manzano, T., & Whitford, W. (2023). AI applications for multivariate control in drug manufacturing. In A Handbook of Artificial Intelligence in Drug Delivery (pp. 55-82). Academic Press.
22. . Rathore, A. S., Nikita, S., Thakur, G., & Mishra, S. (2023). Artificial intelligence and machine learning applications in biopharmaceutical manufacturing. Trends in Biotechnology, 41(4), 497-510.
23. Jariwala, N., et al. (2023). Intriguing of pharmaceutical product development processes with the help of artificial intelligence and deep/machine learning or artificial neural network. Journal of Drug Delivery Science and Technology, 104751.
24. Ranebennur, R., Thirumaleshwar, S., Somareddy, H. K., Desai, R., & Sandeep, D. S. (2023). Development of Automated Quality Assurance Systems for Pharmaceutical Manufacturing: A Review. Journal of Coastal Life Medicine, 11, 1855-1864.
25. Tangi, L., van Noordt, C., & Rodriguez Müller, A. P. (2023, July). The challenges of AI implementation in the public sector. An in-depth case studies analysis. In Proceedings of the 24th Annual International Conference on Digital Government Research (pp. 414-422).
26. Askin, S., et al. (2023). Artificial Intelligence Applied to clinical trials: Opportunities and challenges. Health and Technology, 13(2), 203-213.
27. Bhattamisra, S. K., Banerjee, P., Gupta, P., Mayuren, J., Patra, S., & Candasamy, M. (2023). Artificial Intelligence in Pharmaceutical and Healthcare Research. Big Data and Cognitive Computing, 7(1), 10.